A new version of tenofovir may result in a better-tolerated replacement for Truvada. Read More
A new study examines HIV drug resistance associated with PrEP, and what it could mean as this highly-effective prevention strategy becomes more prevalent. Read More
A recent New York Times article explains the science behind a new advance that could contribute to a successful HIV vaccine. Read More
An integrase inhibitor fared well in a head-to-head comparison with a protease inhibitor regimen for people just starting ART. Find out why this is surprising and what it could mean for treatment naïve people with high viral loads. Read More
Placing HIV and hepatitis C drugs on “specialty” tiers affects their access and affordability. Supervisor Scott Wiener called attention to this issue during a recent San Francisco hearing.